Psychedelics & Chronic Pain

We are taught to think of pain as a simple alarm: damage the tissue, ring the bell. But that model collapses in the face of chronic pain, where the bell keeps ringing with no fire left to warn of. Modern pain science has been forced to a stranger, more powerful conclusion — that pain is not a reading piped up from the body, but a construction the brain builds, and that in chronic pain that construction gets stuck “on.” Understand pain as a learned brain pattern, and a radical therapeutic idea comes into focus: the same drugs that loosen the brain’s stuck patterns in depression might loosen them in pain, too.

When pain outlives its cause

The first thing to understand is that chronic pain is often a different beast from acute pain. Acute pain is nociceptive — a faithful signal of tissue damage that fades as you heal. But a large share of chronic pain is nociplastic: pain arising from a change in how the nervous system itself processes signals, rather than from ongoing injury. Through a process called central sensitization, the spinal cord and brain turn up the gain — amplifying, maintaining, and even generating pain until the alarm system becomes the disease. This is the picture in fibromyalgia, many chronic headaches, and much neuropathic and back pain: the hurt is real, but it is being manufactured by a sensitized, over-learned circuit. And a learned circuit is, in principle, something that can be un-learned.

The surprising anti-pain pharmacology

This is where psychedelics get interesting, because their core target is deeply entangled with pain. Psychedelics are 5-HT2A receptor agonists, and serotonin is one of the brain’s master regulators of pain: the descending modulatory pathways that run from the brainstem down into the spinal cord — the body’s own volume knob for incoming pain — are richly serotonergic, and activating them dampens the pain signal before it ever reaches consciousness. Beyond the spinal cord, Castellanos and colleagues proposed that psychedelics’ ability to “reset” maladaptive functional connectivity — the same large-scale rewiring seen in depression — could unwind the central sensitization that sustains chronic pain (Castellanos et al., 2020). In this view a psychedelic doesn’t numb pain like an opioid; it goes after the network that’s generating it.

Rewiring the pain brain

If chronic pain is a maladaptive pattern burned into neural circuitry, then the most exciting property of psychedelics may be the one that matters most for depression too: neuroplasticity. Psychedelics rapidly promote synaptic growth through BDNF-TrkB signaling, opening a window in which entrenched circuits become malleable again — a chance to re-wire a nervous system that has learned to hurt. At the same time, they exert potent anti-inflammatory effects through the very same 5-HT2A receptor, and neuroinflammation is a key driver of central sensitization. So the proposed mechanism is a three-part convergence: turn up descending inhibition at the spinal cord, quiet the neuroinflammation feeding sensitization, and reset the maladaptive connectivity while plasticity is high — and, ideally, use the psychological opening to change a person’s whole relationship to their pain. It is a fundamentally different strategy from masking a signal.

What the human evidence shows

The mechanism is elegant, but does it help real patients? The honest answer: the early human data are limited, mostly small, and genuinely intriguing. The strongest signal comes from cluster headache — among the most excruciating conditions known — where Emmanuelle Schindler’s team ran a randomized, double-blind, placebo-controlled trial of a low-dose psilocybin pulse and saw a meaningful drop in attack frequency (Schindler et al., 2022). Crucially, the benefit did not track the intensity of the acute trip — a strong hint that, for pain, the mechanism may be pharmacological rather than mystical. In a remarkable phantom-limb case, a single psilocybin session paired with mirror therapy produced immediate, lasting, near-complete relief of pain that had resisted everything else (Ramachandran et al., 2018). And open-label work in fibromyalgia — the archetypal nociplastic condition — has reported preliminary safety and symptom improvement with psilocybin-assisted therapy (Glynos et al., 2025). A 2024 scoping review pulls these threads together across cluster headache, phantom-limb, neuropathic and nociplastic pain (scoping review, 2024).

Pain, suffering, and the mind in the loop

There is also a psychological layer that a purely pharmacological story misses. Chronic pain is not just a sensation; it is a life reshaped — fused with fear, helplessness, depression, and catastrophizing, the mental loop that magnifies and entrenches suffering. Because chronic pain and depression share circuitry and often travel together, the same experiences that help depression — a loosening of rigid negative self-focus, a renewed sense of agency and meaning — may loosen pain’s grip from the top down. Some patients describe not that the sensation vanished, but that their relationship to it changed: the pain stopped being a totalizing threat. This mind-body duality is a feature, not a bug — it’s why psychedelic pain research is being built around psychedelic-assisted therapy, pairing the molecule’s plasticity with psychological support, rather than a pill handed out in isolation.

The honest limits

Real restraint is essential here, because desperate people are watching this field closely. The human evidence is early-stage: small samples, several open-label or single-case reports, short follow-ups, and powerful placebo and expectancy effects that are especially strong in pain. No psychedelic is an approved treatment for any pain condition, and these are potent, still-illegal substances that are unsafe for some people — including those with a personal or family history of psychosis or bipolar disorder, and those on serotonergic medications. Pain patients are also frequently on complex medication regimens that raise real interaction concerns. What is legitimately exciting is the convergence: a coherent, testable mechanism — descending inhibition, reduced neuroinflammation, and a reset of maladaptive connectivity during a plasticity window — lining up with early clinical signals in some of the most treatment-resistant pain conditions in medicine. That is a serious scientific lead worth rigorous trials, not a green light for self-treatment. The promise is real; so is the need for caution.

OOTW Journal is educational and does not provide medical advice. Psychedelics remain controlled substances in most countries and are not safe for everyone, including people with a personal or family history of psychosis or bipolar disorder, and those on serotonergic medications. Nothing here is a recommendation to use any psychedelic or to change any pain treatment. If you are living with chronic pain, please work with a qualified medical professional.